Business Context and Reporting Period
Adial Pharmaceuticals, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2024. The clinical-stage biopharmaceutical company is focused on addiction-related therapies, principally AD04 for alcohol use disorder (AUD). It has no products approved for sale and has not generated significant product revenue. Purnovate was sold in 2023 and is reported as discontinued operations.
Financial Highlights
| Metric | Q1 2024 | Q1 2023 or prior period |
|---|---|---|
| Revenue | No significant product revenue | No significant product revenue |
| Research and development expense | $454,278 | $365,616 |
| General and administrative expense | $1,390,744 | $1,903,159 |
| Total operating expenses / operating loss | $1,845,022 | $2,268,775 |
| Net loss | $6,476,560 | $2,905,836 |
| Operating cash used | $1,626,236 | $2,298,813, including discontinued operations |
| Cash and cash equivalents | $5,025,110 at March 31, 2024 | $2,827,082 at December 31, 2023 |
| Total liabilities | $562,731 | $653,076 at December 31, 2023 |
There is no meaningful gross margin measure because the company has no product sales. The balance sheet reports no debt; liabilities shown are current operating liabilities. No income tax provision was recorded.
Changes Versus the Prior Comparable Period
- R&D expense rose about 24% ($88,000), reflecting increased development planning, chemistry/manufacturing work and personnel costs, partly offset by lower regulatory consulting and direct clinical-trial costs.
- G&A expense fell about 27% ($512,000), mainly due to lower personnel, director compensation, legal, patent, travel and stock-compensation costs following the Purnovate sale and related organizational changes.
- Net loss increased by about $3.57 million, primarily because of a $4.46 million non-cash warrant inducement expense and a $190,000 Adovate equity-method investment loss. These were partly offset by lower operating expenses and the absence of Purnovate discontinued-operation losses.
- Continuing operating cash use increased about $88,000 year over year. Financing provided $3.82 million in Q1 2024, principally from warrant exercises; cash increased by $2.20 million during the quarter.
Liquidity, Outlook and Risks
Management says quarter-end cash is expected to fund operations only into the first quarter of 2025 and is insufficient for the twelve months following the filing. The company states that substantial doubt exists about its ability to continue as a going concern and that additional capital is required. It has no fixed financing commitments and cannot assure that further funding will be available on acceptable terms.
In March, warrant exercises generated approximately $4.0 million gross and $3.82 million net. As an inducement, the company issued Series C warrants covering 2.3 million shares and recorded a one-time $4.46 million non-cash expense. After quarter-end, it sold 178,447 shares through its ATM for $382,250 net proceeds. The ATM permits eligible sales with a stated aggregate market value of $4,283,650 and charges a 3% commission.
Management estimates approximately $4.9 million of cash use for AD04 development and corporate expenses over the twelve months ended March 31, 2025 under accelerated plans. Two additional Phase 3 trials are currently estimated to cost $8–12 million each in direct expenses, plus up to $5 million in other development costs; estimates may change following regulatory discussions and final trial designs. A May 2024 clinical research statement of work commits the company to approximately $1.4 million, payable upon milestones. Without more funding, Adial may delay, reduce or discontinue development activities. Equity financing could dilute shareholders; debt or licensing arrangements could impose restrictions or require surrendering valuable rights.
AD04 development and potential approval remain uncertain. The company is pursuing regulatory discussions after the ONWARD Phase 3 trial and is focusing on specified genetic subgroups. It expects potential commercialization no earlier than 2026. The UVA license includes milestones, royalties and diligence obligations, including stated targets for an FDA NDA by December 31, 2024 and commercialization by December 31, 2025; failure to meet obligations could give the licensor termination rights. The filing reports no pending legal actions as of March 31, 2024.
Management disclosed material weaknesses in internal controls, including insufficient formal risk assessment and documentation, approval and review-process deficiencies, limited complex-GAAP expertise, IT-control deficiencies and insufficient segregation of duties. Management concluded disclosure controls were not effective as of quarter-end.
Important Facts to Verify
- Whether Adial can raise sufficient capital before its projected runway ends, and the resulting dilution or financing terms.
- Regulatory feedback, final trial designs, costs, timing and funding for the proposed AD04 Phase 3 program.
- The practical availability of ATM financing and the remaining amount eligible for sale after subsequent issuances.
- The potential dilution from the 2.3 million Series C warrant shares and other outstanding warrants and options.
- Progress in remediating internal-control material weaknesses and the status of AD04’s license milestones and diligence requirements.